文献速递胸部肿瘤

赛沃替尼联合奥希替尼治疗EGFR突变晚期非小细胞肺癌伴MET过表达和/或扩增且奥希替尼进展后的患者:II期SAVANNAH研究主要结果

Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.
PubMed 文献 · Ann Oncol · 2025-06-02

SAVANNAH研究评估赛沃替尼联合奥希替尼用于EGFR突变晚期NSCLC伴MET过表达和/或扩增且一线奥希替尼进展的患者。主要疗效人群中研究者评估确认的ORR为56.3%,中位缓解持续时间7.1个月,中位无进展生存期7.4个月;盲态独立中心审查结果一致。联合方案耐受性良好,可能提供一种新的口服靶向治疗选择。

要点

  • 主要疗效人群(MET IHC3+/≥90%和/或FISH10+,赛沃替尼300mg每日两次联合奥希替尼)确认ORR为56.3%。
  • 主要疗效人群中位缓解持续时间7.1个月,中位无进展生存期7.4个月。
  • 赛沃替尼联合奥希替尼治疗中最常见任何级别不良事件为外周水肿(46.0%)、恶心(40.5%)和腹泻(23.2%)。

核心结论

  • 赛沃替尼300mg每日两次联合奥希替尼在EGFR突变晚期NSCLC伴MET IHC3+/≥90%和/或FISH10+且一线奥希替尼进展的患者中显示出高且具有临床意义、持久的缓解。
  • 该联合方案耐受性良好,可能为该人群提供一种新的口服靶向治疗选择。

研究设计与样本

  • II期SAVANNAH研究(NCT03778229),纳入EGFR突变晚期NSCLC伴MET过表达和/或扩增的患者。
  • MET初始cut-off为IHC3+/≥50%和/或FISH5+,初步分析后提高至IHC3+/≥90%和/或FISH10+。
  • 患者接受口服赛沃替尼(300mg每日两次、每日一次或600mg每日一次)联合奥希替尼80mg每日一次,或赛沃替尼300mg每日两次联合安慰剂。
  • 主要终点之一为研究者评估的客观缓解率,在既往一线奥希替尼进展且MET IHC3+/≥90%和/或FISH10+、接受赛沃替尼300mg每日两次联合奥希替尼的患者(主要疗效人群)中评估。
  • 安全性在所有接受赛沃替尼联合奥希替尼的患者中分析。

主要发现

  • 共365例患者接受治疗,其中341例接受赛沃替尼联合奥希替尼,80例纳入主要疗效人群。
  • 主要疗效人群中研究者评估确认ORR为56.3%(95%CI 44.7%至67.3%),中位缓解持续时间7.1个月(95%CI 5.6至9.6个月),中位无进展生存期7.4个月(95%CI 5.5至7.6个月)。
  • 盲态独立中心审查结果一致:确认ORR 55.0%(95%CI 43.5%至66.2%),中位缓解持续时间9.9个月(95%CI 6.0至13.7个月),中位无进展生存期7.5个月(95%CI 6.4至11.3个月)。
  • 接受赛沃替尼联合奥希替尼的患者中最常见任何级别不良事件为外周水肿(46.0%)、恶心(40.5%)和腹泻(23.2%)。

关键数值与推荐

  • MET IHC3+/≥50%定义为≥50%肿瘤细胞3+强度;FISH5+定义为MET基因拷贝数≥5或MET/7号染色体着丝粒比值≥2。
  • MET IHC3+/≥90%和/或FISH10+为初步分析后采用的cut-off。
  • 赛沃替尼给药方案包括300mg每日两次、300mg每日一次或600mg每日一次;奥希替尼80mg每日一次。

临床怎么用

  • 作者认为赛沃替尼300mg每日两次联合奥希替尼可能为该人群提供一种新的口服靶向治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MET-based resistance following osimertinib treatment for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) is common. We report the primary analysis of the phase II SAVANNAH study (NCT03778229) evaluating savolitinib plus osimertinib in this setting. PATIENTS AND METHODS: Patients had EGFR-mutated, advanced NSCLC with MET overexpression and/or amplification. MET cut-offs were initially MET immunohistochemistry (IHC)3+/≥50% (3+ intensity in ≥50% of tumor cells) and/or FISH5+ (≥5 MET gene copies or MET/chromosome 7 centromere ratio ≥2), and increased to MET IHC3+/≥90% and/or FISH10+ after a preliminary analysis. Patients received oral savolitinib [300 mg twice daily (b.i.d.) or once daily (o.d.), or 600 mg o.d.] plus osimertinib 80 mg o.d., or savolitinib 300 mg b.i.d. plus placebo. A primary endpoint was investigator-assessed objective response rate (ORR) in patients with progression on first-line osimertinib and MET IHC3+/≥90% and/or FISH10+ status receiving savolitinib 300 mg b.i.d. plus osimertinib (primary efficacy population). Safety was analyzed in all patients receiving savolitinib plus osimertinib. RESULTS: Of the 365 patients treated, 341 received savolitinib plus osimertinib, with 80 of these included in the primary efficacy population. Investigator-assessed confirmed ORR in the primary efficacy population was 56.3% [95% confidence interval (CI) 44.7% to 67.3%]; the median duration of response (mDoR) was 7.1 months (95% CI 5.6-9.6 months); the median progression-free survival (PFS) was 7.4 months (95% CI 5.5-7.6 months). Blinded independent central review was consistent: confirmed ORR 55.0% (95% CI 43.5% to 66.2%); mDoR 9.9 months (95% CI 6.0-13.7 months); median PFS 7.5 months (95% CI 6.4-11.3 months). The most common any grade adverse events in patients receiving savolitinib plus osimertinib were peripheral edema (46.0%), nausea (40.5%), and diarrhea (23.2%). CONCLUSIONS: Savolitinib 300 mg b.i.d. plus osimertinib demonstrated high, clinically meaningful and durable responses in patients with EGFR-mutated, advanced NSCLC with MET IHC3+/≥90% and/or FISH10+ status following progression on first-line osimertinib. The combination was well tolerated and may provide a new oral targeted treatment approach in this setting.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. de Marinis F, Kim TM, Bonanno L, et al. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. Ann Oncol. 2025. PMID: 40461383. doi:10.1016/j.annonc.2025.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。